Imbruvica

(Ibrutinib)

ApprovedSmall molecule

Ibrutinib is used to treat certain types of blood cancers, including chronic lymphocytic leukemia and mantle cell lymphoma, by slowing or stopping the growth of cancer cells.[2] Imbruvica is currently approved and in use across 62 indications[4].[1]

Imbruvica is one of 849 small molecule programs targeting Hemolytic Anemia. It is currently in Approved.

Indications

310

Total Trials

Active Trials

848

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Hemolytic AnemiaActive, not recruiting

Follicular LymphomaCompleted

Central Nervous System LymphomaCompleted

Richter's TransformationRecruiting

Relapsed/refractoryCompleted

Grade 3a Follicular LymphomaActive, not recruiting

Pancreatic NeoplasmApproved

Hodgkins LymphomaApproved

Lung CancerApproved

Liver DiseaseApproved

Hemolytic AnemiaPhase 2

Active, not recruiting

Follicular LymphomaPhase 3

Completed

Central Nervous System LymphomaPhase 2

Completed

Richter's TransformationPhase 2

Recruiting

Relapsed/refractoryPhase 2

Completed

Grade 3a Follicular LymphomaPhase 2

Active, not recruiting

Pancreatic NeoplasmApproved

Approved

Hodgkins LymphomaApproved

Approved

Lung CancerApproved

Approved

Liver DiseaseApproved

Approved

Showing 10 of 62 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Imbruvica

PPharmacyclics LLC.

Approved

1 2

Adenocard

Astellas

Preclinical

2 3

Zolymbus

AbbVie

Preclinical

1 4

Lexiscan

Astellas

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 6

Duragesic

CCephalon

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Tricor

JJagotec

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

CLL-Like MBL

NCT05694312

Phase 1/2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT03153202

Phase 1Active, not recruiting

Lymphoma

NCT03479268

Phase 1Active, not recruiting

Mantle Cell Lymphoma

NCT02159755

Phase 2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT02518555

Phase 2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT03513562

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia38 trials

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Completed·PPharmacyclics LLC.·Phase 2·NCT01744691·145 enrolled

Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

Completed·JJohnson & Johnson Private Limited··NCT03476655·40 enrolled

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03720561·312 enrolled

Show 35 more trials

Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Recruiting·PPaolo Ghia·Phase 2·NCT04758975·55 enrolled

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01611090·578 enrolled

Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

Completed·MMayo Clinic·Phase 2·NCT02649387·35 enrolled

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT02662296

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03425591·508 enrolled

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Withdrawn·MMichael Choi·Phase 1·NCT02611908

Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression

Completed·GGerman CLL Study Group·Phase 3·NCT02863718·515 enrolled

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Completed·GGerman CLL Study Group·Phase 3·NCT02950051·926 enrolled

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Withdrawn·KKerry Rogers·Phase 2·NCT03943342

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Completed·GGrupo Cooperativo de Hemopatías Malignas·Phase 2·NCT03755947·3 enrolled

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Completed·PPharmacyclics LLC.·Phase 3·NCT02264574·229 enrolled

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01886859·27 enrolled

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Completed·UUniversity of California, San Diego·Phase 1/2·NCT02315768·32 enrolled

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Completed·TTG Therapeutics, Inc.·Phase 3·NCT02301156·126 enrolled

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting·KKerry Rogers·Phase 1/2·NCT02427451·87 enrolled

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Completed· AbbVie logo

AbbVie·Phase 2·NCT05105841·20 enrolled

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed·PPharmacyclics LLC.·Phase 3·NCT01578707·391 enrolled

A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)

Completed·MM.D. Anderson Cancer Center·Phase 2/3·NCT02801578·11 enrolled

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

Active, not recruiting·FFrench Innovative Leukemia Organisation·Phase 2·NCT03734198·29 enrolled

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Completed·JJennifer Woyach·Phase 1·NCT02303392·34 enrolled

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03207555·23 enrolled

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Terminated·MMayo Clinic·Phase 2·NCT04230304·8 enrolled

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Completed·JJohnson & Johnson Private Limited·Phase 4·NCT03190330·75 enrolled

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Active, not recruiting·JJennifer Woyach·Phase 1·NCT03447808·15 enrolled

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting·JJennifer Woyach·Phase 2·NCT02518555·42 enrolled

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Active, not recruiting·OOhio State University Comprehensive Cancer Center·Phase 2·NCT03513562·28 enrolled

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Active, not recruiting·—·Phase 1·NCT02537613·54 enrolled

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04781855

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting·VVA Office of Research and Development·Phase 2·NCT06520098·100 enrolled

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT02388048·19 enrolled

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Active, not recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 2·NCT03226301·230 enrolled

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Completed· BeiGene logo

BeiGene·Phase 3·NCT03734016·652 enrolled

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Active, not recruiting·JJoshua Brody·Phase 1/2·NCT03153202·23 enrolled

A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

Recruiting·JJeanette Lundin·Phase 1/2·NCT04771507·50 enrolled

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02733042·106 enrolled

Mantle Cell Lymphoma27 trials

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01599949·120 enrolled

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04662255·500 enrolled

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT02736617·10 enrolled

Show 24 more trials

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05564052·36 enrolled

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02269085·8 enrolled

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

Completed·PPharmacyclics LLC.·Phase 3·NCT03112174·366 enrolled

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT05864742·40 enrolled

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Unknown status·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT02682641·50 enrolled

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03219047·1 enrolled

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02427620·131 enrolled

CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

Recruiting·—·Phase 2·NCT06482684·150 enrolled

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

Unknown status·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT02471391·37 enrolled

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT03232307

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03617484

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Unknown status·NNorthwestern University·Phase 2·NCT02242097·37 enrolled

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03710772·51 enrolled

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Terminated·AADC Therapeutics S.A.·Phase 1/2·NCT03684694·136 enrolled

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02159755·28 enrolled

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Recruiting·PProf. Dr. M. Dreyling (co-chairman)·Phase 3·NCT02858258·870 enrolled

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Withdrawn·AAcerta Pharma BV·Phase 3·NCT02735876

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01776840·523 enrolled

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Completed·LLund University Hospital·Phase 2·NCT02460276·50 enrolled

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02169180·16 enrolled

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01646021·280 enrolled

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Withdrawn·OOncternal Therapeutics, Inc·Phase 3·NCT05431179

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Terminated·SSwiss Cancer Institute·Phase 1/2·NCT02356458·58 enrolled

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Approved for marketing· Johnson & Johnson logo

Johnson & Johnson··NCT01833039

Lymphoma19 trials

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04739813·55 enrolled

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Completed·UUniversity of Washington·Phase 2·NCT02207062·20 enrolled

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

Completed·UUniversity of Cologne·Phase 2·NCT02626884·14 enrolled

Show 16 more trials

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Terminated·NNational Cancer Centre, Singapore·Phase 2·NCT03093831·5 enrolled

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT02869633·23 enrolled

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Completed· Incyte logo

Incyte·Phase 1·NCT03424122·50 enrolled

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02542514·52 enrolled

Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02272686·1 enrolled

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02309580·14 enrolled

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02703272·72 enrolled

Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

Unknown status·HHuiqiang Huang·Phase 2·NCT04514393·33 enrolled

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02743546

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas

Terminated·TThe Lymphoma Academic Research Organisation·Phase 1·NCT02055924·85 enrolled

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02401048·61 enrolled

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·KKami Maddocks·Phase 1·NCT02950220·2 enrolled

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01955499·39 enrolled

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT02824029·28 enrolled

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Active, not recruiting·—·Phase 1·NCT03479268·18 enrolled

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Completed·PPharmacyclics LLC.·Phase 2·NCT01980628·63 enrolled

Diffuse Large B-Cell Lymphoma11 trials

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05211336·14 enrolled

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Completed· Incyte logo

Incyte·Phase 1/2·NCT02760485·33 enrolled

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01855750·838 enrolled

Show 8 more trials

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

Completed·UUniversity Hospital Muenster·Phase 2·NCT03399513·40 enrolled

Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Completed·PPharmacyclics LLC.·Phase 2·NCT01325701·78 enrolled

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03939182·15 enrolled

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Terminated·HHackensack Meridian Health·Phase 1·NCT03136497·10 enrolled

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 1·NCT02780830

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT02692248·64 enrolled

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02142049·35 enrolled

TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT02874404·13 enrolled

Macroglobulinemia10 trials

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Completed·PPharmacyclics LLC.·Phase 3·NCT02165397·181 enrolled

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT03679624·1 enrolled

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Terminated·—·Phase 1·NCT03225716·13 enrolled

Show 7 more trials

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Completed·XX4 Pharmaceuticals·Phase 1·NCT04274738·16 enrolled

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04062448·16 enrolled

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07169565·21 enrolled

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

Completed· BeiGene logo

BeiGene·Phase 3·NCT03053440·201 enrolled

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Completed·—·Phase 2·NCT02604511·31 enrolled

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Active, not recruiting·CChristian Buske·Phase 2·NCT03620903·53 enrolled

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

Active, not recruiting·CChristian Buske·Phase 2·NCT04263480·99 enrolled

64 more indications

Follicular Lymphoma6 trials

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Completed·GGeorgetown University·Phase 1/2·NCT02956382·24 enrolled

Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT02689869·98 enrolled

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02532257·48 enrolled

Show 3 more trials

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02966730·2 enrolled

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Completed·PPharmacyclics LLC.·Phase 2·NCT01980654·80 enrolled

Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

Terminated·SSwiss Cancer Institute·Phase 2·NCT02451111·190 enrolled

Treatment6 trials

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Active, not recruiting·PPharmacyclics Switzerland GmbH·Phase 4·NCT03229200·297 enrolled

Biomarker Guided Treatment in DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT04025593·128 enrolled

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Completed·PPharmacyclics LLC.·Phase 3·NCT01722487·269 enrolled

Show 3 more trials

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT02514083·29 enrolled

Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

Recruiting·PPaolo Ghia·Phase 2·NCT04908228·53 enrolled

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Active, not recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 2·NCT04639362·85 enrolled

Central Nervous System Lymphoma4 trials

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02315326·93 enrolled

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04129710·120 enrolled

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03703167·25 enrolled

Show 1 more trial

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03581942·18 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma3 trials

A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02556892·8 enrolled

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT03204188·15 enrolled

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT04209621·3 enrolled

Multiple Myeloma3 trials

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Terminated·PPharmacyclics LLC.·Phase 1/2·NCT02548962·11 enrolled

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Completed·PPharmacyclics Switzerland GmbH·Phase 2·NCT02902965·74 enrolled

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Completed·PPharmacyclics LLC.·Phase 1/2·NCT01962792·84 enrolled

Chronic Graft Versus Host Disease3 trials

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Recruiting·MMayo Clinic·Phase 2·NCT06271616·40 enrolled

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03474679·19 enrolled

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02195869·45 enrolled

Relapsed/Refractory2 trials

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02759016·7 enrolled

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1/2·NCT04494503·123 enrolled

Acute Lymphoblastic Leukemia2 trials

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

Recruiting·BBrian Jonas·Phase 2·NCT02997761·20 enrolled

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Withdrawn·UUniversity of Utah·Phase 1·NCT02815059

Hemolytic Anemia2 trials

Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia

Unknown status·EEugene Nikitin·Phase 2·NCT03827603·50 enrolled

The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04398459·18 enrolled

Leukemia2 trials

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01973387·160 enrolled

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03514017·5 enrolled

Hematologic Malignancies2 trials

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT02352558·15 enrolled

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1/2·NCT02329847·144 enrolled

Lenalidomide2 trials

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02636322·60 enrolled

LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)

Active, not recruiting·IInstitut Curie·Phase 1/2·NCT04446962·118 enrolled

ESS2 trials

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02841150·102 enrolled

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02877225·103 enrolled

Myelodysplastic Syndrome2 trials

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Completed·BBrian Jonas·Phase 1·NCT02553941·21 enrolled

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Completed·UUniversity of California, Davis·Phase 1·NCT03359460·4 enrolled

Richter's Transformation2 trials

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Recruiting·—·Phase 2·NCT05672173·20 enrolled

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Terminated·NNorthwell Health·Phase 2·NCT03145480·3 enrolled

Refractory2 trials

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03642236·122 enrolled

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT04994626·20 enrolled

Relapse2 trials

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Active, not recruiting·—·Phase 1·NCT02787369·3 enrolled

RICE-ibrutinib in Relapsed DLBCL

Unknown status·SSingapore General Hospital·Phase 2·NCT02955628·34 enrolled

B-cell Malignancies1 trial

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Withdrawn·—·Phase 1·NCT04043845

PCNSL1 trial

Real World Data on Ibrutinib Use in PCNSL Rel/Ref

Active, not recruiting·IIRCCS San Raffaele··NCT05782374·36 enrolled

Pancreatic Adenocarcinoma1 trial

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Completed·PPharmacyclics LLC.·Phase 3·NCT02436668·430 enrolled

Combination Therapy1 trial

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02599324·263 enrolled

Clinical Trial1 trial

PRECISE CURATE.AI Pilot Clinical Trial

Unknown status·NNational University Hospital, Singapore·Phase 1/2·NCT04522284·20 enrolled

Bone Marrow Transplantation1 trial

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Completed· Incyte logo

Incyte·Phase 3·NCT03112603·330 enrolled

Acute Myeloid Leukemia1 trial

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·SSteven E. Coutre·Phase 1·NCT02635074·2 enrolled

Chronic Lymphocytic Leukaemia (CLL)1 trial

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting·GGerman CLL Study Group·Phase 3·NCT04608318·897 enrolled

B-cell NHL1 trial

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04876092·45 enrolled

Non-Small Cell Lung Cancer1 trial

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02950038

Pancreatic Neuroendocrine Tumor1 trial

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02575300·20 enrolled

TIA1 trial

Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Completed·GGerman CLL Study Group·Phase 2·NCT02345863·66 enrolled

Absorption1 trial

A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01674322·6 enrolled

Waldenstrom macroglobulinemia1 trial

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Terminated·MMayo Clinic·Phase 2·NCT03506373·21 enrolled

Acute Leukemia1 trial

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Completed·AAndrew Rezvani·Phase 2·NCT03267186·8 enrolled

Metastatic Solid Tumors1 trial

Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT03525925·16 enrolled

Chronic GVHD1 trial

Ibrutinib and Rituxan for Chronic GVHD

Terminated·NNorthside Hospital, Inc.·Phase 2·NCT04235036·15 enrolled

B-cell Malignancy1 trial

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02381080·26 enrolled

Gastric Carcinoma1 trial

Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT02884453·17 enrolled

Phase II1 trial

Phase II Trial GA101 Inbrutinib B CLL

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT02666898·135 enrolled

Kidney Cancer1 trial

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

Completed·UUniversity of California, Davis·Phase 1/2·NCT02899078·31 enrolled

Breast Cancer1 trial

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Active, not recruiting·UUS Oncology Research·Phase 1/2·NCT03379428·34 enrolled

Pancreatic Cancer1 trial

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Completed·MMargaret Tempero·Phase 1/2·NCT02562898·18 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03310619·62 enrolled

Systemic Mastocytosis1 trial

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Terminated·JJason Robert Gotlib·Phase 2·NCT02415608·4 enrolled

Amyloidosis1 trial

Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

Withdrawn·MMayo Clinic·Phase 2·NCT03130348

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02390609·40 enrolled

Observational Study1 trial

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University··NCT04094051·580 enrolled

Age1 trial

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Active, not recruiting·MMichael Choi·Phase 1·NCT03422393·24 enrolled

Prostate Cancer1 trial

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT02643667·27 enrolled

HIV infection1 trial

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT02109224·72 enrolled

Brain Cancer1 trial

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Recruiting·TTheodore S. Johnson·Phase 1·NCT05106296·37 enrolled

COVID-191 trial

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Withdrawn·—·Phase 2·NCT04665115

Trial1 trial

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Completed·UUniversity of Ulm·Phase 2·NCT02758665·41 enrolled

B-cell Lymphoid Malignancies1 trial

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Completed·OOncternal Therapeutics, Inc·Phase 1/2·NCT03088878·95 enrolled

Metastatic1 trial

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Active, not recruiting·UUniversity of California, San Diego·Phase 2·NCT03646461·5 enrolled

Prospective1 trial

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT03980002·50 enrolled

Immune1 trial

Autoimmune Cytopenia and BcR Inhibitors

Unknown status·IInstitut Paoli-Calmettes··NCT03469895·40 enrolled

Atrial Fibrillation1 trial

Unknown status·UUniversity Hospital, Caen··NCT06224452·18,000 enrolled

Elderly Patients1 trial

Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

Completed·PProf. Dr. Clemens Schmitt·Phase 1/2·NCT03129828·38 enrolled

Safety and Efficacy1 trial

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Completed·—·Phase 1·NCT02268851·45 enrolled

High Risk1 trial

Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.

Terminated·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02670317·1 enrolled

Anaphylaxis1 trial

Inhibition of Anaphylaxis by Ibrutinib

Completed·—·Phase 2·NCT03149315·6 enrolled

TED1 trial

Ibrutinib + Venetoclax in Untreated WM

Active, not recruiting·—·Phase 2·NCT04273139·45 enrolled

Unspecified2 trials

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Unknown status·PPETHEMA Foundation·Phase 2·NCT03280160·84 enrolled

ECP Combination Study

Completed·EEuropean Society for Blood and Marrow Transplantation··NCT05052385·319 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 13, 2013

IMBRUVICA

NDA NDA205552

Jan 29, 2015

IMBRUVICA

NDA NDA205552

Aug 13, 2015

IMBRUVICA

NDA NDA205552

Aug 17, 2015

IMBRUVICA

NDA NDA205552

Aug 24, 2015

IMBRUVICA

NDA NDA205552

Nov 25, 2015

IMBRUVICA

NDA NDA205552

Feb 8, 2016

IMBRUVICA

NDA NDA205552

Mar 4, 2016

IMBRUVICA

NDA NDA205552

Mar 21, 2016

IMBRUVICA

NDA NDA205552

Apr 13, 2016

IMBRUVICA

NDA NDA205552

May 6, 2016

IMBRUVICA

NDA NDA205552

May 6, 2016

IMBRUVICA

NDA NDA205552

Jun 27, 2016

IMBRUVICA

NDA NDA205552

Jun 28, 2016

IMBRUVICA

NDA NDA205552

Jan 18, 2017

IMBRUVICA

NDA NDA205552

Jul 10, 2017

IMBRUVICA

NDA NDA205552

Aug 2, 2017

IMBRUVICA

NDA NDA205552

Dec 20, 2017

IMBRUVICA

NDA NDA205552

Dec 20, 2017

IMBRUVICA

NDA NDA205552

Feb 16, 2018

IMBRUVICA

NDA NDA210563

Aug 24, 2018

IMBRUVICA

NDA NDA205552

Aug 24, 2018

IMBRUVICA

NDA NDA210563

Aug 24, 2018

IMBRUVICA

NDA NDA205552

Jan 25, 2019

IMBRUVICA

NDA NDA205552

Jan 25, 2019

IMBRUVICA

NDA NDA210563

Jul 15, 2019

IMBRUVICA

NDA NDA205552

Jul 15, 2019

IMBRUVICA

NDA NDA210563

Nov 21, 2019

IMBRUVICA

NDA NDA210563

Nov 21, 2019

IMBRUVICA

NDA NDA205552

Apr 21, 2020

IMBRUVICA

NDA NDA205552

Apr 21, 2020

IMBRUVICA

NDA NDA210563

Aug 7, 2020

IMBRUVICA

NDA NDA205552

Aug 7, 2020

IMBRUVICA

NDA NDA210563

Dec 18, 2020

IMBRUVICA

NDA NDA210563

Dec 18, 2020

IMBRUVICA

NDA NDA205552

Dec 22, 2020

IMBRUVICA

NDA NDA210563

Dec 22, 2020

IMBRUVICA

NDA NDA205552

May 11, 2022

IMBRUVICA

NDA NDA205552

May 11, 2022

IMBRUVICA

NDA NDA210563

Aug 24, 2022

IMBRUVICA

NDA NDA217003

Aug 24, 2022

IMBRUVICA

NDA NDA210563

Aug 24, 2022

IMBRUVICA

NDA NDA210563

Aug 24, 2022

IMBRUVICA

NDA NDA205552

Aug 24, 2022

IMBRUVICA

NDA NDA205552

Aug 24, 2022

IMBRUVICA

NDA NDA210563

Aug 24, 2022

IMBRUVICA

NDA NDA205552

Aug 24, 2022

IMBRUVICA

NDA NDA217003

May 18, 2023

IMBRUVICA

NDA NDA210563

May 18, 2023

IMBRUVICA

NDA NDA205552

Feb 22, 2024

IMBRUVICA

NDA NDA217003

May 9, 2024

IMBRUVICA

NDA NDA205552

May 9, 2024

IMBRUVICA

NDA NDA217003

May 9, 2024

IMBRUVICA

NDA NDA210563

Dec 20, 2024

IMBRUVICA

NDA NDA205552

Dec 20, 2024

IMBRUVICA

NDA NDA217003

Dec 20, 2024

IMBRUVICA

NDA NDA210563

Oct 21, 2025

IMBRUVICA

NDA NDA217003

Oct 21, 2025

IMBRUVICA

NDA NDA205552

Oct 21, 2025

IMBRUVICA

NDA NDA210563

Sources

References

[1]
ClinicalTrials.gov — 310 trial records for Ibrutinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Imbruvica drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ibrutinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ibrutinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217003). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Imbruvica. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Pharmacyclics LLC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tyrosine-Protein Kinase BTK Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: PPharmacyclics LLC.

Patent Landscape[6]

Patent Cliff

Dec 28, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8754091Dec 28, 2026

8703780Dec 28, 2026

8697711Dec 28, 2026

8952015Dec 28, 2026

8497277Dec 28, 2026

79 more patents

8476284Dec 28, 2026

7514444Dec 28, 2026

8735403Dec 28, 2026

8957079Dec 28, 2026

9181257Dec 28, 2026

8563563Apr 26, 2027

8952015*PEDJun 28, 2027

8697711*PEDJun 28, 2027

8703780*PEDJun 28, 2027

8735403*PEDJun 28, 2027

8497277*PEDJun 28, 2027

8957079*PEDJun 28, 2027

9181257*PEDJun 28, 2027

8476284*PEDJun 28, 2027

8754091*PEDJun 28, 2027

7514444*PEDJun 28, 2027

8563563*PEDOct 26, 2027

8008309Nov 13, 2027

8008309*PEDMay 13, 2028

9801883Jun 3, 2031

10653696Jun 3, 2031

11672803Jun 3, 2031

10016435Jun 3, 2031

10478439Jun 3, 2031

10751342Jun 3, 2031

10004746Jun 3, 2031

9125889Jun 3, 2031

9814721Jun 3, 2031

9801881Jun 3, 2031

8754090Jun 3, 2031

8999999Jun 3, 2031

9125889*PEDDec 3, 2031

10016435*PEDDec 3, 2031

10478439*PEDDec 3, 2031

8754090*PEDDec 3, 2031

10653696*PEDDec 3, 2031

8999999*PEDDec 3, 2031

9814721*PEDDec 3, 2031

9801881*PEDDec 3, 2031

9801883*PEDDec 3, 2031

10004746*PEDDec 3, 2031

10751342*PEDDec 3, 2031

10752634Jun 3, 2033

10961251Jun 3, 2033

10125140Jun 3, 2033

10106548Jun 3, 2033

9725455Jun 3, 2033

9713617Jun 3, 2033

10294231Jun 3, 2033

10294232Jun 3, 2033

9540382Aug 18, 2033

9296753Oct 30, 2033

10294231*PEDDec 3, 2033

9725455*PEDDec 3, 2033

10752634*PEDDec 3, 2033

10106548*PEDDec 3, 2033

10125140*PEDDec 3, 2033

10294232*PEDDec 3, 2033

10961251*PEDDec 3, 2033

9713617*PEDDec 3, 2033

9540382*PEDFeb 18, 2034

9296753*PEDApr 30, 2034

9795604Oct 24, 2034

10463668Oct 24, 2034

10695350Oct 24, 2034

9795604*PEDApr 24, 2035

10463668*PEDApr 24, 2035

10695350*PEDApr 24, 2035

9655857Mar 3, 2036

12551448Mar 3, 2036

10828259Mar 3, 2036

10010507Mar 3, 2036

10213386Mar 3, 2036

12364698Apr 6, 2036

10010507*PEDSep 3, 2036

10213386*PEDSep 3, 2036

10828259*PEDSep 3, 2036

9655857*PEDSep 3, 2036

12201690Jun 14, 2039

Imbruvica

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Chronic Lymphocytic Leukemia38 trials

Mantle Cell Lymphoma27 trials

Lymphoma19 trials

Diffuse Large B-Cell Lymphoma11 trials

Macroglobulinemia10 trials

Follicular Lymphoma6 trials

Treatment6 trials

Central Nervous System Lymphoma4 trials

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma3 trials

Multiple Myeloma3 trials

Chronic Graft Versus Host Disease3 trials

Relapsed/Refractory2 trials

Acute Lymphoblastic Leukemia2 trials

Hemolytic Anemia2 trials

Leukemia2 trials

Hematologic Malignancies2 trials

Lenalidomide2 trials

ESS2 trials

Myelodysplastic Syndrome2 trials

Richter's Transformation2 trials

Refractory2 trials

Relapse2 trials

B-cell Malignancies1 trial

PCNSL1 trial

Pancreatic Adenocarcinoma1 trial

Combination Therapy1 trial

Clinical Trial1 trial

Bone Marrow Transplantation1 trial

Acute Myeloid Leukemia1 trial

Chronic Lymphocytic Leukaemia (CLL)1 trial

B-cell NHL1 trial

Non-Small Cell Lung Cancer1 trial

Pancreatic Neuroendocrine Tumor1 trial

TIA1 trial

Absorption1 trial

Waldenstrom macroglobulinemia1 trial

Acute Leukemia1 trial

Metastatic Solid Tumors1 trial

Chronic GVHD1 trial

B-cell Malignancy1 trial

Gastric Carcinoma1 trial

Phase II1 trial

Kidney Cancer1 trial

Breast Cancer1 trial

Pancreatic Cancer1 trial

Relapsed/Refractory B-cell Malignancies1 trial

Systemic Mastocytosis1 trial

Amyloidosis1 trial

Colorectal Cancer1 trial

CLL-like MBL1 trial

Adult1 trial

Observational Study1 trial

Age1 trial

Prostate Cancer1 trial

HIV infection1 trial

Brain Cancer1 trial

COVID-191 trial

Trial1 trial

B-cell Lymphoid Malignancies1 trial

Metastatic1 trial

Prospective1 trial

Immune1 trial

Atrial Fibrillation1 trial

Elderly Patients1 trial

Safety and Efficacy1 trial

High Risk1 trial

Anaphylaxis1 trial

TED1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]